StreetInsider.com News Articles

Eikon Therapeutics doses first patient in lung cancer trial

Mon, 27 Jul 2026 07:30:11 -0400

Eikon Therapeutics (Nasdaq: EIKN) announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating its drug candidate EIK1001 in non-small cell lung cancer (NSCLC).

The global, multicenter, double-blind, placebo-controlled, randomized trial is testing EIK1001 administered intravenously in combination with pembrolizumab and histology-appropriate chemotherapy as a first-line therapy for treatment-naïve patients with Stage 4 NSCLC. The study covers both non-squamous and squamous histologies, with chemotherapy regimens varying by subtype.

TeLuRide-008 will be conducted in two phases and analyzed in three parts: dose optimization, dose expansion, and confirmatory hypothesis testing. It is the second registrational Phase 2/3 trial

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Mon, 27 Jul 2026 07:30:00 -0400

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC).

“Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue to advance EIK1001 in multiple indications, with the ultimate goal of delivering improved

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Mon, 27 Jul 2026 07:30:00 -0400

“Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue to advance EIK1001 in multiple indications, with the ultimate goal of delivering improved

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Mon, 20 Jul 2026 08:00:00 -0400

Presentations to cover updates across Eikon’s clinical pipeline including:

Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer (NSCLC)
Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors
Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer
Initial results from an ongoing Phase 1/2 study of EIK1004, a

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Mon, 20 Jul 2026 08:00:00 -0400

Presentations to cover updates across Eikon’s clinical pipeline including:

Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer (NSCLC)
Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors
Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer
Initial results from an ongoing Phase 1/2 study of EIK1004, a

Eikon Therapeutics to join Russell 3000 index on June 26

Thu, 25 Jun 2026 16:15:11 -0400

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a clinical-stage biopharmaceutical company, announced it will be added to the Russell 3000® Index following the annual reconstitution, effective after the U.S. market closes on June 26, 2026.

The Russell 3000 Index tracks approximately 3,000 stocks designed to represent 98% of the investable U.S. equity market, spanning large-cap, mid-cap, and small-cap equities. The index is reconstituted annually each June, with a semi-annual reconstitution set to begin in December 2026.

Eikon, based in Millbrae, Calif., focuses on oncology and is advancing a pipeline of drug candidates targeting cancers with high unmet medical need.

Eikon Therapeutics to join Russell 3000 index on June 26

Thu, 25 Jun 2026 16:15:11 -0400

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a clinical-stage biopharmaceutical company, announced it will be added to the Russell 3000® Index following the annual reconstitution, effective after the U.S. market closes on June 26, 2026.

The Russell 3000 Index tracks approximately 3,000 stocks designed to represent 98% of the investable U.S. equity market, spanning large-cap, mid-cap, and small-cap equities. The index is reconstituted annually each June, with a semi-annual reconstitution set to begin in December 2026.

Eikon, based in Millbrae, Calif., focuses on oncology and is advancing a pipeline of drug candidates targeting cancers with high unmet medical need.

Eikon Therapeutics to Join the Russell 3000® Index

Thu, 25 Jun 2026 16:15:00 -0400

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, effective after the US market closes on June 26, 2026.

The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth/value/defensive/dynamic). The Russell 3000

Eikon Therapeutics to Join the Russell 3000® Index

Thu, 25 Jun 2026 16:15:00 -0400

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, effective after the US market closes on June 26, 2026.

The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth/value/defensive/dynamic). The Russell 3000

Eikon Therapeutics to Join the Russell 3000® Index

Thu, 25 Jun 2026 16:15:00 -0400

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, effective after the US market closes on June 26, 2026.

The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth/value/defensive/dynamic). The Russell 3000

Eikon Therapeutics to Join the Russell 3000® Index

Thu, 25 Jun 2026 16:15:00 -0400

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, effective after the US market closes on June 26, 2026.

The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth/value/defensive/dynamic). The Russell 3000

Eikon Therapeutics appoints Ma. Fatima Francisco to board of directors

Mon, 08 Jun 2026 08:00:09 -0400

Eikon Therapeutics, Inc. (NASDAQ: EIKN) announced the appointment of Ma. Fatima Francisco as an independent director to its board of directors, effective June 15, 2026. Francisco will also serve on the board's compensation committee.

Francisco previously served as Chief Executive Officer of Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she held leadership positions across marketing, innovation, commercial operations and general management.

Francisco currently serves on the boards of directors of HP Inc. and Nestle S.A., and previously

Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors

Mon, 08 Jun 2026 08:00:00 -0400

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma. Fatima ("Fama") D. Francisco as an independent director to Eikon’s Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board.

"Fama brings a remarkable record of leadership, innovation and talent development from one of the world's most successful global enterprises," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive

Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors

Mon, 08 Jun 2026 08:00:00 -0400

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma. Fatima ("Fama") D. Francisco as an independent director to Eikon’s Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board.

"Fama brings a remarkable record of leadership, innovation and talent development from one of the world's most successful global enterprises," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive

Eikon Therapeutics (EIKN) Reiterated at Overweight by Cantor Fitzgerald

Tue, 02 Jun 2026 07:29:26 -0400

Cantor Fitzgerald analyst Imogen Mansfield reiterated an Overweight rating on Eikon Therapeutics Inc. (NASDAQ: EIKN).
The analyst commented, "We think EIKN's PARP1 inhibitors have best-in-class potential and could meaningfully grow the size of the "PARP pie," offering earlier-line combinability and expansion into BRCAwt patients. We estimate product launch for EIK1003/4 in 2031 with >$1.5B peak sales across indications, and continue to assume a 60% POS for this program. We see EIK1001 as a high risk/high reward opportunity. Data from early clinical studies and the Ph2 NSCLC cohort provide signs of encouragement, but conclusive evidence of superiority over control arms (pembro/chemo in

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Sat, 30 May 2026 14:30:00 -0400

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development
Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations